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Abstract
Background: Although ivermectin is distributed free of charge through the African Programme for Onchocerciasis 
Control (APOC), not all eligible individuals within communities receive the annual treatment. This poses a serious threat 
to efforts aimed to control onchocerciasis. This study attempts to determine factors associated with compliance to 
Community Directed Treatment with Ivermectin (CDTI) and provides a basis for trying to understand how best to 
sustain long-term compliance in order to achieve success in the control of onchocerciasis.
Methods: An unmatched case-control study was conducted in Bebeka coffee plantation southwest Ethiopia. Cases 
were, compliant i.e., those individuals who had been registered on the relevant treatment registers and had taken all 
the five annual doses of Ivermectin. Controls were non-compliant, i.e. those individuals who had been recorded in the 
relevant treatment registers during the first treatment round(2003), and did not take at least two doses of which one 
being in the last treatment round (2007). Data were collected using a pre-tested interviewer administered structured 
questionnaire. Data were edited, cleaned, coded and analyzed using SPSS version 12.0.1 for Microsoft Windows. 
Multiple logistic regression models was used to identify factors associated with compliance to ivermectin.
Results: From the total of 456 individuals selected for administration of the survey questionnaire, 450(225 cases and 
225 controls) were contacted and completed the study 2 refused and 4 were unavailable. Five factors associated with 
compliance were identified: high risk perception [Adjusted Odds Ratio(AOR) = 1.98, 95% Confidence Interval (CI), 1.32-
2.95], one's family support [AOR = 1.86, 95% CI, 1.22-2.84], perceiving that the Community Drug Distributors (CDDs) are 
doing their work well [AOR = 2.84, 95% CI, 1.50-5.37] and perceiving measuring height is the best way to determine a 
person's treatment dose [AOR = 6.37, 95% CI, 2.10-19.29] are positive predictors of compliance to ivermectin.
Conclusion: Interventions to improve compliance in the area should focus on health education using epidemiological 
data in order to increase risk perception and dispelling misconceptions. Motivation and continued support to improve 
CDD's performance including training and incentives are crucial.
Background
Onchocerciasis, "river blindness", is a parasitic disease
caused by a filarial worm, Onchocerca volvulus. The dis-
ease is transmitted by the blood feeding black fly, of the
genus Simulium [1]. Onchocerciasis is endemic in many
tropical countries but mainly in the equatorial region of
Africa. According to recent estimates, 37 million people
are infected worldwide and 90 million are at risk in Africa
[2].
In Ethiopia, 3 million people are already infected,
whereas 7.3 million are at risk of infection and almost
everyone in an endemic village will harbor the disease.
Nine regions surveyed for river blindness were shown to
be endemic; the endemic areas extend from the north-
west part to southwest part of the country that borders
Sudan [3,4]. The main symptom of the disease in the
country is dermal (skin) manifestations that are charac-
terized by disabling intense itching and thickening of the
skin, hanging groin etc. Blindness, which is a common
manifestation of the disease in West Africa, is a rare com-
plication in Ethiopia, which is located in East Africa [3].
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The prevalence of onchocerciasis in the country ranges
from 85.3% in Teppi province, southwestern Ethiopia to
6.9% in the Kuwara province of Northwest Ethiopia [5].
Onchocerciasis has been targeted for control, at least as
a disease of public health and socio-economic develop-
ment importance, in Ethiopia along with other 19 African
countries [3]. Mass treatment of high risk communities
with ivermectin is adopted in line with the African Pro-
gram for Onchocerciasis Control (APOC)'s Community
Directed Treatment with ivermectin (CDTI) strategy,
since 1996 [6]. CDTI is in which the community itself has
the responsibility for organizing and executing treatment
of its members. CDTI is based on the principle of active,
structural community participation [7,8]. The process
empowers community members to make major decisions
and direct the distribution of ivermectin for a sustained
period of years. Examples of community decisions made
with respect to mass treatment include: dates of distribu-
tion; mode of distribution (e.g. house-to-house, central
place); persons who will guide distribution; and selection
of the community implementers, also known as Commu-
nity- Directed Distributors (CDDs). In addition to mak-
ing such planning decisions, communities take
responsibility for: conducting a community census, col-
lecting drug supplies, mobilizing members during the
drug distribution process, as well as recording treatments
provided and coverage attained [9].
The drug ivermectin (trade name, Mectizan®) is a
microfilaricide and a temporary microfilarial suppres-
sant, which was approved in 1978 for mass treatment of
communities exposed to onchocerciasis. Treatment has
to be continued annually for at least 10 years in order to
cover the life span of the adult worms, which are not
killed by this drug [10]. All members of households in the
communities will be treated with ivermectin 150 mg/kg
body weight in each round provided there are no con-
traindications. Contraindications for administration of
ivermectin include being younger than 5 years or 90 cen-
timeters in height, being pregnant or and lactation of
infant less than one week of age, having serious health
problem, e.g. asthma, renal or hepatic disease. Before
administering the drug, community members will be
informed about the disease and possible adverse reac-
tions following therapy as well as the availability of help
for any untoward reactions. They are then weighed and
asked to swallow the drug on the spot [10,11].
To achieve the target, the treatment must continue for
15-20 years [12] with sustained compliance and commu-
nity coverage of at least 90% [13]. Together with coverage,
compliance was found to be an important factor for the
success of the program through assurance of adequate
reduction (to control serious onchocerciasis and, eventu-
ally, to have a significant impact on transmission) in
transmission of the parasite and thus a good degree of
protection from further infection [4].
In the African region, several studies showed that mass
treatment with ivermectin resulted in a major reduction
in transmission of onchocerciasis [14]. However, revival
of transmission has been noticed following disruption of
ivermectin treatment before an optimal duration of the
lifespan of adult O. volvulus worms (ten years above) [1].
The largest trial, undertaken in the hyper-endemic
focus of Asubende on the river Pru in Ghana, provided
the most detailed information on the effect of mass treat-
ment on transmission, showing a major reduction in vec-
tor infectivity but still significant residual transmission
after treatment [15] and a subsequent increase in infec-
tivity levels to near pretreatment levels 12 months later
[8]. Hence, high treatment coverage and sustained com-
pliance are given due emphasis in disease control pro-
grams of onchocerciasis in order to ensure its
effectiveness.
Though compliance plays an important role in the suc-
cess of onchocerciasis control, except for some anecdotes
like perceived benefits and dangers of ivermectin treat-
ment that are frequently cited as reasons for compliance
and non-compliance respectively, there are no scientifi-
cally documented explanations that can provide a direct
insight into why individual community members do or do
not take ivermectin in the study area. In addition, only
few similar studies could be found elsewhere [16-18] that
can help answer the questions associated with compli-
ance with CDTI.
This study, therefore, identifies factors associated with
CDTI compliance and provides a basis for understanding
how to sustain community control efforts over a long
period to achieve success in the control of onchocerciasis
as a public health and socioeconomic problem. This
study attempted to answer one primary research ques-
tion: (1) what factors are associated with CDTI compli-
ance and what are the motivators and barriers of
compliance with CDTI?
Methods
Setting
The study was conducted in Bebeka coffee plantation
(farm), between February 1 and February 28, 2008. The
study area is found Southwest Ethiopia, which is located
595 Kilometers South West of Addis Ababa. The area has
a range of altitude between 900 and 1000 meters above
sea level with annual rainfall of about 1728 millimeters.
There are two major rivers in the area that are responsible
for vector Simulidae (black flies) breeding namely; Aware
and Gatcheb. The total population of the farm is 17164
(Bench-Maji zonal Economy & Finance Development
Department, projected for the year 2007) and they reside
in 20 villages.Yirga et al. Parasites & Vectors 2010, 3:48
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As part of the control program, annual mass treatment
has been started in the plantation since 2003 by World
Health Organization (WHO)/APOC in partnership with
Ethiopian Federal Ministry of Health, The Carter Centre,
the local administration and the communities. Up to 2008
February, five treatment rounds have already taken place
with CDTI strategy. Drug distribution is being carried
out by CDDs under the supervision and technical assis-
tance by health extension workers, nurses and health offi-
cers. Most of the villages have maintained complete and
consistent annual treatment records using the APOC's
treatment registration books. (Table 1)
Design
The study employed an unmatched case - control study
design. Cases were, compliant i.e., those individuals who
had been registered on the relevant treatment registers
and had taken all the five annual doses of Ivermectin.
Controls were, non-compliant, those individuals who had
been recorded in the relevant treatment registers during
the first treatment round (2003), and didn't take at least
two doses of which one being in the last treatment round
(2007). All individuals living in the study area and regis-
tered on the registration book since the first treatment
round (i.e., 2003) are considered as source population for
this study. Individuals exempted from treatment because
of treatment ineligibility (i.e., under 5 years old or 90 cm
tall; having serious health problem, e.g. asthma, preg-
nancy and lactation of infant less than one week of age)
were excluded from the study. Those who are aged less
than 15 years were excluded.
Sample size and sampling procedure
During initial assessment, it was found that most of the
villages (14 out of 20) have maintained complete and con-
sistent annual treatment records using the APOC's treat-
m e n t  r e g i s t r a t i o n  b o o k s .  F i v e  v i l l a g e s  w e r e  s e l e c t e d
randomly among the 14 villages included in the study. In
the selected villages, there were 5014 individuals of which
2287 were found to be registered since 2003 for annual
mass treatment. From the treatment registration books of
the selected villages, all individuals who were eligible
(1351) for the study were stratified into controls and
cases. Meanwhile, cases and controls were listed sepa-
rately on two different sampling frames to the size of 477
cases and 874 controls. After excluding those individuals
who permanently left the area or died after the last treat-
ment round from the list, a table of computer-generated
random numbers was used to select the final cases (n =
228) and controls (n = 228) using simple random sam-
pling.
The sample size was calculated using Epi-Info version
3.4.1 statistical software (Statcalc) by considering the fol-
lowing parameters: 95%CI, 80% power and 1; 1 ratio for
controls and cases. By taking a significant risk factor from
a Uganda study [16] i.e., 'perceived risk of having
onchocerciasis with magnitude of 76% & 91% in non-
compliers & compliers, respectively, the sample size
required were 108 cases and108 controls. We also
assumed a design effect of two and by adding 10% for
non-responses in both groups; the total sample size was
456 (228 cases and 228 controls).
The selected cases and controls were then traced back
in the community using their address and with the help of
village leaders and CDDs. If the prospective interviewee
was not present during the visit and could not be found
even after three visits, he or she was considered a non-
responder.
In-depth interviews using a semi-structured interview
guide were conducted with eight key informants that
were selected based on their affiliation with CDTI and
the community, from health workers, community repre-
sentatives and CDDs. The interview was conducted by a
person who was trained and who had sufficient informa-
tion about the program and the area.
Measurements
The structured questionnaire, which was developed after
an intensive literature review on the subject, was trans-
lated into Amharic and pre-tested on areas not included
Table 1: Population and Annual ivermectin Treatment Coverage of the Study Villages, Bebeka coffee plantation, Southwest Ethiopia, 
February 2008
Village name Total no of population in the village Individuals in the study Annual ivermectin community treatment coverage
2003 2004 2005 2006 2007
Gatcheb 1179 94 66% 56% 51% 62% 75%
Awarie 350 47 70% 34% 64% 81% 87%
Hamsa-sidist 1113 79 63% 58% 72% 61% 68%
Nib-erbata 688 91 69% 62% 85% 77% 72%
Olme Gojeb 1684 145 52% 57% 61% 56% 63%Yirga et al. Parasites & Vectors 2010, 3:48
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in the study. Compliance to ivermectin is defined as the
extent to which individual members of the communities
t a k e  i v e r m e c t i n  a t  e a c h  a n n u a l  d i s t r i b u t i o n  s i n c e  t h e
inception of CDTI in the village. The definition is based
on the number of dose(s) missed in specified treatment
rounds, as reviewed from the treatment registration
books. An individual was identified as compliant if he or
she was registered on the registration book since the first
treatment round (i.e., 2003), and took all five doses. On
the other hand, an individual was identified as non-com-
pliant if he or she was registered on the registration book
since the first treatment round and had missed at least
two of the five doses of ivermectin of which one non-
treatment being in the last treatment round.
Data were collected by a pre-tested questionnaire,
which was adopted, from different studies. A wide range
of independent variables was utilized. Socio-demo-
graphic characteristics included: age categorized into two
groups (≤35, and >35), sex, average monthly family
income, education divided into three categories (no for-
mal education, primary or less school, secondary and
above), religion, marital status divided into two categories
(married and currently not in marriage), employment sta-
tus, duration of stay in the plantation (<10 years and≥10
years). Knowledge about onchocerciasis was measured
with 11 questions emphasizing cause, transmission and
prevention which assessed the knowledge of the individu-
als. Knowledge was scored by giving 0 for incorrect
answers and 1 for correct answers. Perceived risk of
onchocerciasis was measured with 3 questions. Each of
the questions required a response on a four point scale
(very high to very low). Perceived benefits of ivermectin
are defined as the respondents' perception regarding the
benefits of ivermectin. Respondents were said to have
good/right perception if they mentioned that "ivermectin
prevents onchocerciasis with or without mentioning
expelling intestinal worms." Other responses were judged
as wrong perception on the benefit of the drug. Attitude
towards ivermectin was measured with 8 questions. An
example of one such question is "ivermectin will elimi-
nate the parasite causing onchocerciasis from the body".
Response categories ranged from 1 to 4, for strongly dis-
agree to strongly agree. Participation in community
meetings to select CDD, perceived performance of com-
munity drug distributors and best method of dose deter-
mination were measured each by one question.
Potential factors associated with compliance were
grouped into the socio-demographic characteristics such
as age, gender, level of education and occupation, partici-
pant's behavioral factors such as knowledge, belief and
attitudes towards the treatment, the disease, and the ser-
vice, service related factors and social factors.
A semi-structured open-ended interview guide was
used for the key informant interviews. The guide
included questions which assessed the CDTI program,
knowledge and beliefs related to CDTI compliance. On
average each interview took one hour.
Data Analysis
Data were coded and encoded using SPSS version 12.0.1
software. Also, data were cleaned and checked for outli-
ers, inconsistencies and missing values. Knowledge was
scored by giving zero (0) to incorrect answers and 1 for
correct answers. Binary logistic analysis was used to com-
pare socio-demographic characteristics. Odds ratio and
95% confidence interval (CI) were used to measure the
strength of association between the potential factors and
the outcome, i.e. compliance with CDTI. Variables that
were significant at a level of P < 0.10 were considered for
inclusion in multivariate models. Covariates were
retained if they were significant at the 5% level. Finally,
stepwise logistic regression with both forward likelihood
methods were used to control possible confounders and
to identify independent factors associated with CDTI
compliance. The findings were consistent in both forward
and backward likelihood methods.
All tape-recorded interviews were transcribed verba-
tim. The transcribed text from each informant was trans-
lated from Amharic to English. The data were transcribed
and analyzed manually, in line with the objectives of the
study. The translated text document of the note and the
transcribed information were coded. Reading and coding
were initiated while the data were being collected. The
texts were read repeatedly to identify major themes.
Finally an overall interpretation was done, about how the-
matic areas related to one another, explaining how the
various concepts relate one another. These data were
compared with the quantitative data, and some quotes
from the qualitative data were integrated and presented
in parallel with the quantitative information to elaborate
the insights of the participants.
Ethical Considerations
Ethical clearance was obtained from Jimma University
ethical clearance committee of the faculty of public
health. Permission was sought from Bebeka coffee planta-
tion administration and the plantation's labor union. An
informed verbal consent was obtained from every eligible
individual before inclusion into the study by explaining
the objective of the research. Privacy and confidentiality
were ensured.
After the interview, data collectors provided important
information regarding onchocerciasis mainly focusing on
misperceptions and knowledge deficits observed during
the interview with the respondents.
Results
From the total of 456 individuals selected for administra-
tion of the survey questionnaire, 450 were contacted andYirga et al. Parasites & Vectors 2010, 3:48
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completed the study. While two individuals refused to
participate in the study, the remaining four were not
available at home after repeated attempts, yielding a
response rate of 98.7%.
Eight key informants were interviewed, two health
workers, two community representatives and four com-
munity drug distributors (of whom two had dual respon-
sibility as CDD and community leader). All were male,
age above twenty five and except one all have lived in the
area for more than twenty years. Only one health worker,
age twenty six, has reported to have been living in the
area for six years.
Socio-demographic characteristics
Out of the 450 study participants, i.e., 225 cases and 225
controls, the majority (62.7%) of the cases and 72.9% of
the controls were under 35 years of age and 56.9%of the
cases and 52.0% of the controls were male in sex category
as shown in Table 2. Both study groups i.e., cases and
controls, were found to be similar in all but their age and
employment status in that most of the controls (72.9%)
were under 35 years of age showing a statistically signifi-
cant difference from that of the cases (p = 0.03) and sig-
nificantly higher proportion of cases (71.1%) were
employed when compared to the controls (p = 0.01).
Bivariate analysis
As depicted in Table 3 the bivariate analysis of this study
revealed nine variables to be associated with compliance
to community directed ivermectin treatment. Among the
socio-demographic facts, respondents' age and their
employment status showed significant association with
the dependent variable.
Multivariate analysis
A fully adjusted logistic regression model was developed
t h a t  i n c l u d e d  n i n e  e x p o s u r e  v a r i a b l e s.  A s  a  r e s u l t  f i v e
independent predictors of compliance to CDTI were
identified; employment, high risk-perception, family sup-
port, perceived performance of CDDs as good and believ-
ing the best method of one's dose determination is
measuring height. As to the employment status,
employed individuals were more likely to comply with
ivermectin treatment when compared to unemployed
individuals [AOR = 1.68, 05% CI 1.11-2.61] and those
individuals who assumed themselves at high risk of get-
ting onchocerciasis were almost twice as likely to comply
with the treatment than individuals who have low or no
risk perception [OR = 1.98, 95% CI 1.32-2.95] as shown in
Table 4.
Family support was another independent factor associ-
ated with compliance in this study with individuals per-
ceiving that their families are supportive to take the
treatment were 1.86 times more likely to comply with the
treatment than those who do not perceive their families
as supportive[AOR = 1.86, 95% CI 1.22-2.84].
Likewise, perceiving that the CDDs were doing their
work well or very well was also identified as an indepen-
dent factor associated with compliance. Individuals who
perceived CDDs as doing their work well or very well are
2.84 times more likely to comply with the treatment than
individuals who perceived CDD's performance as poor
and very poor [AOR = 2.84, 95% CI 1.50-5.37]. Similarly
the qualitative result of our study indicated poor perfor-
mance of CDDs. A 45-year old community leader said "...
the ability of drug distributors is under question mark.
First, I don't think they have enough training on the dis-
ease and the treatments they are giving. They do not have
better information than the community itself. This has
been observed during the distribution times. The com-
munity members believed that they (CDDs) have suffi-
cient knowledge and they usually ask different questions,
and drug distributors sometimes give wrong or irrelevant
answers. As a result, either they (the community mem-
bers) will be misled or may lose confidence on the distrib-
utor (CDD)".
Finally, the strongest variable associated with compli-
ance in this study was found to be the method of ivermec-
tin dose determination. As shown in Table 3, individuals
who perceived that measuring height is the best way of
one's dose determination were 6.37 times more likely to
comply with the treatment than individuals who per-
ceived that measuring height is not the best way of one's
dose determination [AOR = 6.37, 95% CI 2.10-19.29]. In
our qualitative result most of the informants indicated
that they were usually asked by community members
about the correctness of measuring height to determine
one's dosage.
A CDD, while explaining the issue said that:
".. I remember, individuals (members of the village)
usually ask the correctness of measuring height for dose
determination. We (drug distributors) always tell them
that the method is approved and recommended by the
health service. But there are some incidents in which I
myself was puzzled. By measuring height, we sometimes
give equal dose of the drug for people who are widely dif-
ferent in age and weight. I remember, for example, a
mother that asked why she and her daughter are given
equal number of tablets. Of course though they were
equal in height, the mother was too fat and apparently
older in age when compared to her very young and slen-
der daughter. Both have taken three tablets. I don't think
it (the drug) will work for the mother. In my opinion, it is
not logical that people with different weight and age
should take equal doses. The dosage might be different if
weight was considered instead of height. I'm not still con-
vinced about the accuracy of measuring height for dose
determination."Yirga et al. Parasites & Vectors 2010, 3:48
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With regard to the CDTI program, the experiences of
the key informants concerning the communities' partici-
pation in community meetings that were (if any) intended
to collectively select CDDs and determine date of the
drug distribution. Accordingly, most of the key infor-
mants said that there were no special meetings in the
communities on these issues but selection of the most of
the CDDs was performed by the health service. One com-
munity representative, when explaining his experience
about the selection process, he said that;
"... individuals who were working in polio vaccination
campaign were assigned by the health center workers to
distribute the drugs; I don't remember special community
meeting that was conducted to select these people".
Another key informant (health worker), said that;
"...some communities have conducted meetings to select 
community drug distributors, but in some communities 
especially replacements of new CDDs by those who 
stopped up working as CDD was carried out by the health 
center and the near by health stations based on their will-
ingness, ability to read and write \and prior participation 
in other health activities."
Regarding the date of drug distribution, all of the key
informants similarly said that the distribution time was
not decided by the community. The annual distribution
activity takes place in almost similar times of the years,
April or May, as the drugs are sent to the area from Zonal
health department.
The key informants think that CDDs are performing
well. However, the performance of CDDs is not with out
Table 2: Socio-demographic characteristics of cases and controls in Bebeka Coffee Plantation, Southwest Ethiopia, February 2008
Variable Case Number (%) Control Number (%) p-value
Age in years (Mean, SD, 31.4, 11.6) (32.7, 11.6) (30.1, 12.1) 0.03*
≤35 141 (62.7) 164 (72.9)
>35 84 (37.3) 61 (27.1)
Sex 0.35
Male 128(56.9) 117 (52.0)
Female 97 (43.1) 108 (48.0)
Current marital status 0.27
Married 154 (68.4) 143(63.6)
Currently not in marriage 71 (31.6) 82(36.4)
Highest grade completed
No formal education 66 (29.3) 67 (29.8) 0.77
Primary education 91 (40.4) 84 (37.3) 0.47
Secondary and post secondary 68 (30.2) 74 (32.9)
Employment status 0.01*
Not-employed 65 (28.9) 90 (40.0)
Employed 160(71.1) 135 (60.0)
Religion 0.46
Christians 211 (93.8) 207 (92.0)
Muslims 14 (6.2) 18 (8.0)
Ethnicity 0.55
Endogenous ethnic groups 40 (17.8) 45(20.0)
Non endogenous ethnic groups 185 (82.2) 180 (80.0)
Duration of stay in Bebeka (Mean, SD, 20.4, 6.5) (20.6, 6.8) (20.2, 6.2) 0.63
< 10 years 16 (7.1) 14 (6.2)
≥10 years 209 (92.9) 211 (93.8)
Monthly average family income(Ethiopian Birr) 0.80
500 and less 186 (82.7) 188 (83.6)
501 and above 39 (17.3) 37 (16.4)
*Statistically significant at p-value <0.05, SD = Standard Deviation, 1$ = 9.7 birrYirga et al. Parasites & Vectors 2010, 3:48
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question, the forty five years old community representa-
tive, when explaining about the CDDs performance said
that;
"...  the ability of drug distributors is under question
mark. First, I don't think that they have got enough train-
ing on the disease and the treatments they are giving. They
do not have better information than the community itself.
This has been observed during the distribution times. As
the community members believe that they (CDDs) have
sufficient knowledge, they usually ask different questions
and drug distributors sometimes give wrong or irrelevant
answers. As a result either they will be misled or may lose
confidence on the distributor (CDD)".
On the number of days the distribution runs at each
treatment round, the participants, especially the CDDs
and the health workers, responded with wide variation.
But as most of the key informants report, the distribution
of ivermectin in the area runs for about a two week
period. However health facilities continue to provide the
treatment for about a month.
On the other hand, the opinions of the key informants
on the factors that help individuals to comply with the
treatment and reasons for non compliance were asked.
Table 3: Variables associated with compliance in bivariate analysis, in Bebeka coffee plantation, Southwest Ethiopia, February 2008
Variable Case No (%) Control No (%) COR (95% CI) p-value
Employment status
Not-employed 65 (28.9) 90 (40.0) 1.0 0.01
Employed 160(71.1) 135 (60.0) 1.64 (1.11-2.43)
Age
35 and lower 141 (62.7) 164 (72.9) 1.0 0.03
36 and above 84 (37.3) 61 (27.1) 1.60(1.07-2.39)
Perceived risk of having the disease
High 124 (55.1) 90 (40.0) 1.84 (1.27-2.68) <0.001
Low 101 (44.9) 135 (60.0) 1.0
Family supports your intake of ivermectin
Yes 154 (68.4) 124 (55.1) 1.77 (1.20-2.60) <0.001
Not accounted 71 (31.6) 101 (44.9) 1.0
Attitude towards the drug
Favorable attitude 140 (64.2) 100 (44.4) 2.06 (1.41-3.00) <0.001
Unfavorable attitude 85 (37.8) 125 (55.6) 1.0
Knowledge about community directed treatment 
with ivermectin
Knowledgeable 88(39.1) 68 (30.2) 1.48 (1.01-2.19) 0.04
Not knowledgeable 137 (60.8) 157 (69.8) 1.0
Participated in community meetings to select 
community drug distributors
Yes 73 (32.4) 51 (22.7) 1.63 (1.07-2.48) 0.02
No 152(67.6) 174 (77.3) 1.0
Perceived performance of community drug 
distributors as
Well and very well 209 (92.9) 178 (79.1) 3.45 (1.89-6.23) <0.001
Poor and very poor 16(7.1) 47 (20.9) 1.0
Measuring height is the best way of dose 
determination
Yes 221 (98.2) 194 (87.4) 7.97 (2.75-23.14) <0.001
No 4 (1.8) 28 (12.6) 1.0
COR = Crude Odds Ration, CI = Confidence IntervalYirga et al. Parasites & Vectors 2010, 3:48
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According to the opinions of most of the key informants,
the drug's ability in expelling intestinal worms, the com-
munities' good perception on the treatment were consid-
ered to be important factors that help individuals to
continuously take the treatment in line with the recom-
mendations of the control program. As to the reasons for
non-compliance, being absent during the treatment time,
fear of side effects and lack of awareness both to the dis-
ease and the treatment were commonly cited by the key
informants as a possible reasons.
Discussion
This study has tried to identify factors that are associated
with compliance to annual doses of ivermectin in the
community directed treatment program of the Bebeka
coffee plantation. Though few similar studies had been
conducted in other African Program for Onchocerciasis
Control (APOC) member African countries, it is the first
in Ethiopia.
In t he adjust ed regression mode l, five varia bles were
shown to be independently associated with compliance.
These five predictors can be classified in three categories
as; individuals' factors, social factors and program-related
factors.
Among the socio-demographic variables, employment
status was positively associated with compliance. This
can be explained by the extent of mobility unemployed
individuals show in the area. Particular to the study set-
ting, it is customary that many of the unemployed indi-
viduals move to areas where casual business
opportunities are available, like a gold mining area,
located 60 km south of the farm, which attracts a lot of
people from different parts of the country. The other pos-
sible explanation for association between non-compli-
ance and unemployment can be associated with the
reaction of students (in this case unemployed) with the
treatment acceptance. However one can not exclude spu-
rious association due to significant baseline difference
between case and controls on employment status. Inter-
estingly our qualitative analysis also showed that many
students refuse to take the treatment in fear of side effects
that could avert them from going to school as the drug's
side effect may last up to one week. Moreover, a shorter
period of ivermectin distribution that lasts for about two
weeks in most communities possibly increases the likeli-
hood of missing these highly mobile segments of the pop-
ulation, thus contributing to non-compliance.
The other factor positively associated with compliance
in this study was high risk perception to the infection of
onchocerciasis, which is consistent with another study
[16]. It is a well-established fact that the likelihood of an
action like treatment intake would increase if the per-
ceived threat of the disease is high [19]. On the other
hand, qualitative results of this study have shown that
Table 4: Independent predictors of compliance with Community Directed Treatment with Ivermectin, Bebeka coffee plantation, 
Southwest Ethiopia, 2008
Variables Case No (%) Control No (%) COR (95% CI) AOR* (95% CI) P-value
Employment status <0.01
Not-employed 65 (28.9) 90 (40.0) 1.0 1.0
Employed 160(71.1) 135 (60.0) 1.64 (1.11-2.43) 1.68 (1.11-2.61)
Perceived risk of having the disease <0.001
High 124 (55.1) 90 (40.0) 1.84 (1.27-2.68) 1.98 (1.32-2.95)
Low 101 (44.9) 135 (60.0) 1.0 1.0
Family supports your intake of ivermectin
Yes 154 (68.4) 124 (55.1) 1.77 (1.20-2.60) 1.86 (1.22-2.84) <0.001
Not accounted 71 (31.6) 101 (44.9) 1.0 1.0
Perceived performance of community drug 
distributors
<0.001
Well and very well 209 (92.9) 178 (79.1) 3.45 (1.89-6.23) 2.84 (1.50-5.37)
Poor and very poor 16(7.1) 47 (20.9) 1.0 1.0
Measuring height is the best way of dose 
determination
<0.001
Yes 221 (98.2) 194 (87.4) 7.97 (2.75-23.14) 6.37 (2.10-19.29)
No 4 (1.8) 28 (12.6) 1.0 1.0
COR = Crud Odds Ratio, AOR = Adjusted Odds Ratio, CI = Confidence interval. * Adjusted for variables indicated in table 2.Yirga et al. Parasites & Vectors 2010, 3:48
http://www.parasitesandvectors.com/content/3/1/48
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health education activities in the area were very weak that
otherwise could provide epidemiological information
that could have probably raised perceived risk of individ-
uals to the disease.
Family members are indicated to be the primary com-
ponent of social support network [20,21] where social
support is an interpersonal process that involves
exchange of information. Information as a means to an
end consists of facts, advice, words of reassurance [22],
positive affirmation [20-22], which affects individual
behaviors and decisions including compliance to medica-
tion. Similarly support of family members to participate
in treatment was also significantly associated with com-
pliance in our study. This was consistent with other study
conducted elsewhere in the region [16].
Our findings also showed that perceived good perfor-
mance of CDDs by the population is associated with
increased compliance. This result is similar to what other
investigators have found out elsewhere [16,17]. It is a
matter of fact that CDDs, to be able to carry out their
tasks, need re-training [23]. This shows that their role as
efficient drug distributor and community health educator
is emphasized in the program. However, our qualitative
study that included CDDs themselves revealed insuffi-
cient knowledge on the side of CDDs that might have
resulted in hampered acceptability by the community. It
was also clearly indicated that the community members
had poor confidence and trust on CDDs having perceived
their performance as incompetent. Some community
members apparently cited lack of trust and confidence on
the CDDs as reason for non compliance. Moreover, some
of CDDs admitted low performances (de-motivation)
related to the interruption of incentives that were pro-
vided at the beginning of the program. The incentives
that included financial incentives, T-shirts and other nec-
essary supplies are no longer supplied since the last two
to three rounds as described by the CDDs.
The strongest factor associated with increased compli-
ance in this study was found to be belief on the use of
measuring height as a proper way to determine some-
body's dose. This concurs with the results from Uganda
[16]. The authors attributed to the "belief in this popula-
tion (particularly among non-compliers) that tall people
are normally weak and therefore risk being overdosed if
height instead of weight is used as a criterion for deter-
mining one's dose of ivermectin".
Similarly our qualitative data showed the communities'
beliefs in that using height for dose determination makes
different people with wide variation in weight receive
equal doses of ivermectin they are taking, which may
result in incorrect dosage. This can be an indication of
the level of health education in the study area. Therefore
it is important to strengthen health education activities in
the project areas to dispel myths such as this.
The results of this study should be interpreted cau-
tiously. First, the study was conducted among a planta-
tion setting, which is structurally different from the
traditional communities. This indicates that the results
cannot necessarily be generalized to other non-planta-
tional communities. The selection of cases and controls
entirely depend on the CDTI register book which may
result in misclassification bias. There were significant dif-
ferences between cases and controls with respect to age
and employment status. Although adjustment for these
factors did not appreciably affect the association, we can-
not rule out residual confounding. Finally we have not
measured history of onchocerciasis which might influ-
ence compliance. With the aforementioned limitations in
mind, we conclude that our findings have implications for
interventions with onchocerciasis control program in the
area and other similar setups.
Conclusion
As programs to control onchocerciasis become more
developed and have completed several annual ivermectin
treatment rounds, it may become necessary to address
the issue of non-compliance through innovative public
health approaches. Designing interventions that reduce
the number of non-compliant persons might make the
difference between successful control of transmission of
onchocerciasis, and mere control of the parasite. To that
end; the distribution should last long enough, at each
treatment round, in order to reach less compliers (eg.
more mobile unemployed village members.), health edu-
cation should focus on epidemiological information in
order to increase risk perception and should target family
members. In addition health education should also incor-
porate information regarding the use of measuring height
as it is equally reliable with measuring weight in determi-
nation of ivermectin dose that somebody should take.
Finally motivation and continual support to improve
CDD's performance including training and incentives are
crucial.
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